<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2301-1254</journal-id>
<journal-title><![CDATA[Anales de la Facultad de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Anfamed]]></abbrev-journal-title>
<issn>2301-1254</issn>
<publisher>
<publisher-name><![CDATA[Universidad de la República. Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2301-12542017000200135</article-id>
<article-id pub-id-type="doi">10.25184/anfamed2017v4n2a8</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Desarrollo de infección tuberculosa latente y efectos adversos de la isoniazida durante tratamiento con biológico por Enfermedad de Crohn]]></article-title>
<article-title xml:lang="en"><![CDATA[Development of latent tuberculosis and adverse effects with isoniazid during biologist therapy´s in Crohn´s Disease]]></article-title>
<article-title xml:lang="pt"><![CDATA[Desenvolvimento de tuberculose latente durante e efeitos adversos da isoniazida o tratamento com biológicos para a Doença de Crohn]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Arriola]]></surname>
<given-names><![CDATA[María Alejandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Secondo]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Avendaño]]></surname>
<given-names><![CDATA[Karla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iade]]></surname>
<given-names><![CDATA[Beatriz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Hospital de Clínicas Clínica de Gastroenterología]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2017</year>
</pub-date>
<volume>4</volume>
<numero>2</numero>
<fpage>135</fpage>
<lpage>144</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2301-12542017000200135&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2301-12542017000200135&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2301-12542017000200135&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: Los fármacos anti factor de necrosis tumoral alfa (TNF-&#945;) bloquean una de las citoquinas implicadas en la patogénesis de la Enfermedad Inflamatoria intestinal (EII). Su uso se relaciona con aumento de tuberculosis (TB), por lo que el despistaje previo es obligatorio. En la infección tuberculosa latente (ITBL) se utiliza isoniazida como quimioprofilaxis, fármaco que no se encuentra libre de reacciones adversas. Se presenta y discute el caso de una paciente con reacción adversa en piel secundaria al uso de isoniazida.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: Anti-tumor necrosis factor alfa drugs are responsible for blocking one of the cytoquines implicated on inflammatory bowel disease pathogenesis. Its use has been linked to an increase in tuberculosis cases which is why screening before starting treatment is mandatory. Latent tuberculosis is treated with isoniazid as chemoprophylaxis although its use may provoke adverse effects. A case is presented of a patient with skin adverse reaction due to the use of isoniazid.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo: Os medicamentos anti factor de necrose tumoral alfa (TNF-&#945; ) bloqueiam uma das citocinas envolvidas na patogénese da doença inflamatória intestinal (DII). A sua utilização está associada com um aumento da tuberculose (TB), de modo que a despistagem anterior dessa doença é necessária. Na TB latente, frequentemente se utiliza a isoniazida é usado como quimioprofilaxia, uma droga que não está livre de reações adversas. Apresentamos e discutimos o caso de uma paciente com reação adversa na pele secundária ao uso da isoniazida.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[anti factor de necrosis tumoral alfa, Isoniazida]]></kwd>
<kwd lng="es"><![CDATA[enfermedad inflamatoria intestinal, Tuberculosis]]></kwd>
<kwd lng="en"><![CDATA[anti-tumor necrosis factor alfa, Isoniazid]]></kwd>
<kwd lng="en"><![CDATA[inflammatory bowel disease, Tuberculosis]]></kwd>
<kwd lng="pt"><![CDATA[anti factor de necrose tumoral alfa, Isoniazida]]></kwd>
<kwd lng="pt"><![CDATA[doença inflamatória intestinal]]></kwd>
<kwd lng="pt"><![CDATA[tuberculose]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Anticuerpos anti-TNF en el tratamiento de la enfermedad inflamatoria intestinal]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hinojosa]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2000</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>250-7</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Tuberculosis Patogenia, diagnóstico y tratamiento]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lozano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<source><![CDATA[Offarm]]></source>
<year>2002</year>
<volume>21</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>102-10</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Recomendaciones sobre tuberculosis y tratamiento de la enfermedad inflamatoria intestinal con infliximab]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-San Román]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Obrador]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fortún]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Gassull]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Gastroenterol Hepatol]]></source>
<year>2006</year>
<volume>29</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>81-4</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rahier]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Magro]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Abreu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Armuzzi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ben-Horin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chowers]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[J Crohns Colitis]]></source>
<year>2014</year>
<volume>8</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>443-68</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Preventive chemotherapy Where has it got us? Where to go next? Int. J. Tuberc]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landry]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Menzies]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Lung Dis]]></source>
<year>2008</year>
<volume>12</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1352-64</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Consensus Document on Prevention and Treatment of Tuberculosis in Patients for Biological Treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mir Viladrich]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Daudén Tello]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Solano-López]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[López Longo]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Taxonera Samso]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Martínez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Bronconeumol]]></source>
<year>2016</year>
<volume>52</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>36-45</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Rates of cutaneous reactions to drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arndt]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Jick]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>1976</year>
<volume>235</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>918-22</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Two years review of cutaneous adverse drug reaction from first line anti-tuberculous drugs]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[WC]]></given-names>
</name>
<name>
<surname><![CDATA[Ong]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Razak]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Med J Malaysia]]></source>
<year>2007</year>
<volume>62</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>143-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Guías de recomendaciones de prevención de infecciones en pacientes que reciben modificadores de la respuesta biológica]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jordán]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Valledor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Arg Reumatol]]></source>
<year>2014</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>08-26</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Adalimumab, etanercept, infliximab, and the risk of tuberculosis data from clinical trials, national registries, and postmarketing surveillance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cantini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Niccoli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Goletti]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[J Rheumatol Suppl]]></source>
<year>2014</year>
<volume>91</volume>
<page-range>47-55</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="book">
<source><![CDATA[Comisión honoraria para la lucha antituberculosa y enfermedades prevalentes. Programa nacional de control de la tuberculosis: Informe año 2014]]></source>
<year>2014</year>
<publisher-loc><![CDATA[Montevideo ]]></publisher-loc>
<publisher-name><![CDATA[Internet Montevideo CHLA-EP]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gamma interferon release assays for detection of Mycobacterium tuberculosis infection]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Denkinger]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Kik]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Rangaka]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zwerling]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Oxlade]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Microbiol Rev]]></source>
<year>2014</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-20</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[General health maintenance in IBD]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moscandrew]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mahadevan]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Kane]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Inflamm Bowel Dis]]></source>
<year>2009</year>
<volume>15</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1399-409</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Infliximab therapy in established rheumatoid arthritis an observational study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Voulgari]]></surname>
<given-names><![CDATA[PV]]></given-names>
</name>
<name>
<surname><![CDATA[Alamanos]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Nikas]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[Bougias]]></surname>
<given-names><![CDATA[DV]]></given-names>
</name>
<name>
<surname><![CDATA[Temekonidis]]></surname>
<given-names><![CDATA[TI]]></given-names>
</name>
<name>
<surname><![CDATA[Drosos]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med]]></source>
<year>2005</year>
<volume>118</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>515-20</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Toxicodermia por metotrexato con marcada dismaduracio´n epide´rmica]]></article-title>
<collab>García de Villalta MJ.Ruiz-Genao D.A´lvarez-Ruiz S.Aragu¨e´s M.Fraga J.Ferna´ndez-Herrera J</collab>
<source><![CDATA[Actas Dermosifiliogr]]></source>
<year>2004</year>
<volume>95</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>567-70</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
